- Changes to anti-infective access restrictions in DHB hospitals
- Ceftaroline fosamil – new treatment for use in DHB hospitals
PHARMAC acknowledges concerns over antibiotic resistance and has been taking steps to protect the effectiveness of currently funded antibiotic treatments. PHARMAC has placed prescribing restrictions on approximately 90% of the funded antimicrobial medicines in public hospitals. This means funded access to these medicines is restricted to specific specialists (such as clinical microbiologists or infectious disease specialists). These restrictions were put in place to help reduce over-prescribing of antibiotics. PHARMAC is continuing this work in relation to antibiotics used in the community.
PHARMAC works closely with the Ministry of Health, Environmental Science and Research (ESR) and other stakeholders in the infectious disease area to support antibiotic stewardship.
From 1 November 2014, PHARMAC added ceftaroline fosamil to the list of medicines funded in DHB hospitals to strengthen their options to defend against multi-resistant bacterial infections. Ceftaroline is a fifth-generation cephalosporin, an updated version of a long line of effective anti-bacterials. It is particularly targeted at people exposed to multi-resistant strains of bacterial infections, more commonly referred to as 'superbugs'.
The addition of this medicine continues our work in ensuring clinicians have access to effective pharmaceutical tools to deal with multi-resistant bacteria.
Last updated: 13 December 2018